NCT07096713Completed
Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema
Evaluating the Efficacy and Safety of Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema: A Retrospective Comparative Study
Source: ClinicalTrials.gov · Last updated 31 Jul 2025
Brief summary (registry, in English)
This retrospective, comparative cohort study included 38 eyes from 38 patients with center-involving diabetic macular edema (DME), treated at Benha University Hospital. Patients were divided into two groups: 19 eyes received intravitreal Brolucizumab (6 mg), and 19 eyes received intravitreal Aflibercept (2 mg), with the aim of comparing their efficacy and safety over a 6-month period.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 38 (actual)
- First submitted
- 24 Jul 2025
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Benha University
- Diseases
- Diabetic eye disease
- NCT number
- NCT07096713
What you commit to
- Study type: Interventional
- Participants enrolled: 38
- From 1 Jan 2024 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with media opacity (e.g., corneal opacities, dense vitreous hemorrhage).
- History of vasculitis or autoimmune diseases (e.g., systemic lupus erythematosus \[SLE\]).
Other
- Significant cataract affecting visual acuity or OCT imaging quality.
- Traction maculopathy or vitreomacular traction.
- Central macular thickness \< 350 µm at baseline.
Who the study is looking for
- Patients diagnosed with center-involving diabetic macular edema (DME) confirmed by spectral-domain optical coherence tomography (SD-OCT).
- Central macular thickness (CMT) \> 350 µm at baseline.
- Treatment-naïve patients (no prior intravitreal injections or laser therapy for DME).
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Benha University Coordinator of this site? Confirm its status | Banhā | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.